In Brief
This article was originally published in The Tan Sheet
Executive Summary
FDA’s Blumberg dies; Hi-tech sales up, income down; Reliv targets U.S. growth; investigation costs slow Omega Protein; AB Biotics launches AB-Dentis worldwide; Liquid Nutrition franchising reaches U.S.; and Ingredion gets fiber approval in Canada.
You may also be interested in...
In Brief
FDA approves OTC HIV test; Good Herbs disclaimer does not cancel drug claims; American Herbal Pharmacopoeia releases blue cohosh monograph; salmonella triggers Standard Process supplement recall; Kemin, Ball see zeaxanthin partnership bloom; more In Brief.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.